𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Similar patterns of genomic alterations characterize primary mediastinal large-B-cell lymphoma and diffuse large-B-cell lymphoma

✍ Scribed by Nallasivam Palanisamy; Ashraf A. Abou-Elella; Seeta R. Chaganti; Jane Houldsworth; Kenneth Offit; Diane C. Louie; Julie Terayu-Feldstein; Juan C. Cigudosa; Pulivarthi H. Rao; Warren G. Sanger; Dennis D. Weisenburger; R.S.K. Chaganti


Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
836 KB
Volume
33
Category
Article
ISSN
1045-2257

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

To address the possible genetic relationship between primary mediastinal large‐B‐cell lymphoma (PMLBCL) and diffuse large‐B‐cell lymphoma (DLBCL), we compared DNA copy number changes identified by comparative genomic hybridization (CGH) analysis of 40 PMLBCL and 91 DLBCL tumors. We assessed their karyotypes by G‐banding; amplification of MYC, BCL2, and REL genes by Southern blotting; and incidence of nonpolymorphic BCL6 mutations by single‐strand conformation polymorphism analysis (SSCP). Overall, CGH identified overlapping and nonoverlapping patterns of DNA copy number changes in the two groups. Among the latter changes, gains of chromosomes 8, 11, 15, and 16 and losses of chromosomes 5, 10, 15, 16, 17, and 20 were seen only in DLBCL, and gains of chromosomes 10, 21, and 22 and losses of chromosomes 11, 13, and 18 were seen only in PMLBCL. Several overlapping changes were identified in both groups, with variation in incidence. Statistical analysis of these changes showed significant gains of chromosomes 3 (P ≤ 0.05) and 7q (P ≤ 0.05) in DLBCL and gains of chromosomes 9 (P ≤ 0.05) and 19 (P ≤ 0.05) and the X chromosome (P ≤ 0.05) and loss of chromosome 4 (P ≤ 0.05) in PMLBCL. Frequent recurring DNA amplification at 2p13‐15 and less frequent amplification at 6p21, 12q13, and 18q21 were noted in both groups. Recurring amplification at 1q21 was seen only in DLBCL, whereas nonrecurring amplification at 10p11.2 and 15q22‐24 was seen only in PMLBCL. G‐banded karyotype analysis identified t(3;14)(q27;q32) in one and t(14;18)(q32;q21) in two cases of PMLBCL. Seven of 13 cases exhibited SSCP variants in the 5′ noncoding region of BCL6. In addition__,__ 19 of 24 PMLBCLs assayed for BCL6 protein expression by immunohistochemistry showed positive results, indicating an origin from a germinal center (GC)–derived B cell. Based on these data, we conclude that PMLBCL is a distinct entity among GC‐derived high‐grade DLBCLs. © 2002 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Primary pulmonary diffuse large B-cell l
✍ Tomasz Wróbel; Justyna Dzietczenia; Monika Prochorec–Sobieszek; Grzegorz Mazur; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 634 KB
Comparison of peripheral T-cell lymphoma
✍ Naoto Tomita; Shigeki Motomura; Rie Hyo; Hirotaka Takasaki; Sachiya Takemura; Ju 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 1 views

## Abstract ## BACKGROUND Peripheral T‐cell lymphomas (PTCLs) are a biologically heterogeneous subgroup of lymphomas with poor prognosis. In this study, the authors analyzed the clinical behaviors of PTCLs and diffuse large B‐cell lymphoma (DLBCL). ## METHODS The authors compared the characteris

Molecular heterogeneity of B-lineage dif
✍ Gisella Volpe; Umberto Vitolo; Antonino Carbone; Cristina Pastore; Marilena Bert 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 948 KB

B-lineage diffuse large cell lymphoma (B-DLCL) arising de novo is chatacterized by a marked degree of clinical heterogeneity. To determine whether or not the clinical heterogeneity of de novo B-DLCL is reflected by heterogeneity in the molecular features of these tumors, we investigated the pattern

Prognostic models for diffuse large b-ce
✍ Annarita Conconi; Emanuele Zucca; Enrico Roggero; Francesco Bertoni; Augusto Ber 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 2 views

Prognosis of DLCL patients is variable and associated with well-de®ned risk factors. In the past decade several pretreatment variables have been incorporated into prognostic models to predict the death risk of individual patients. The International Prognostic Index (IPI), developed in an internation